What NOVA Genomics does

NOVA Genomics, LLC is a privately held, Virginia-based reproductive genetics laboratory founded in 2025 by Dr. Gary Harton and Cynthia Hudson. The company provides preimplantation genetic testing (PGT) services to IVF clinics and fertility practices, screening embryos created through in vitro fertilization for chromosomal aneuploidy (PGT-A), single-gene monogenic disorders such as cystic fibrosis and sickle cell anemia (PGT-M), and inherited structural chromosomal rearrangements (PGT-SR). The company is positioned as a purpose-built PGT laboratory, designed from the ground up to address what its founders describe as gaps in legacy lab technologies, quality and compliance, and access to advanced reproductive genetic services, particularly for PGT-SR and PGT-M cases involving inherited conditions.

The company's underlying platform is a next-generation sequencing and molecular diagnostics workflow operated out of a CLIA-grade laboratory in Manassas, Virginia. NOVA delivers the three PGT assays through direct B2B relationships with IVF clinics and through a channel partnership with IVF Store, an online IVF marketplace; it complements testing with integrated genetic counseling via Tandem Genetics and patient financing via PatientFi. The clinical team includes Medical Director Dr. Harvey Stern (30+ years in PGT and molecular genetics), Director of Clinical Services Mary Sands (certified genetic counselor, 20+ years in IVF clinic integration), and Director of Laboratory Services Dr. Brian Mariani, supported by lab leads in SNV and CNV workflows and advisors including Dr. Darren K. Griffin, co-developer of Karyomapping.

NOVA generates revenue on a per-test laboratory services basis, charging IVF clinics fees for each PGT-A, PGT-M, or PGT-SR case analyzed. Pricing is not publicly disclosed, and the company has not announced external funding rounds, named enterprise customers, or revenue figures. Operating geographies are limited to the United States, and compliance posture includes HIPAA, CCPA/CPRA, and COPPA. As a sub-ten-person, founder-led 2025 startup, NOVA remains in early commercialization with its competitive position resting on the depth of its clinical team and its purpose-built laboratory architecture rather than on disclosed technological differentiation.

Name

NOVA Genomics

Legal name

NOVA Genomics, LLC

Website

https://novagenomics.org

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

NOVA Genomics is a Virginia-based reproductive genetics laboratory founded in 2025 that provides preimplantation genetic testing (PGT-A, PGT-M, PGT-SR) services to IVF clinics and fertility practices in the United States using next-generation sequencing and molecular diagnostics.

Ownership category

akta.pro rank

Product category

Reproductive Genetic Testing Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

Keywords

• Preimplantation genetic testing
• Reproductive genetic testing
• IVF laboratory services
• Embryo genetic screening
• Aneuploidy testing services

Headquarters

HQ city

Manassas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. PGT Laboratory Services: NOVA Genomics generates revenue through laboratory genetic testing services provided to IVF clinics and fertility practices. The company analyzes embryos for chromosomal abnormalities (PGT-A), single-gene disorders (PGT-M), and structural chromosomal rearrangements (PGT-SR), charging per-test fees for each PGT service rendered.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

NOVA Genomics runs a CLIA-certified preimplantation genetic testing (PGT) laboratory that analyzes embryo biopsies created via in vitro fertilization. It offers three tests — PGT-A for chromosomal aneuploidy, PGT-M for monogenic/single-gene disorders, and PGT-SR for structural chromosomal rearrangements — delivered to IVF clinics and fertility practices for use in clinical decision-making.

Product overview

NOVA Genomics offers a unified suite of preimplantation genetic testing (PGT) services for embryos created during in vitro fertilization (IVF). The company provides three distinct testing products: PGT-A screens for chromosomal aneuploidies (extra or missing chromosomes), PGT-M diagnoses single-gene disorders such as cystic fibrosis and sickle cell anemia, and PGT-SR detects structural chromosomal rearrangements inherited from parents. These tests are designed to help physicians and patients make informed clinical decisions during the IVF process.

Differentiator

Problem solved

Functional benefit

Products and services

• PGT-A (Preimplantation Genetic Testing for Aneuploidy) A genetic test to screen embryos (created via IVF) for numerical chromosome changes (aneuploidy), such as Down syndrome. It identifies embryos predicted to have the expected complement of chromosomes and is used by IVF physicians for clinical decision-making.
• PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) A genetic test performed on embryos (created via IVF) to screen for and diagnose inherited variants that cause monogenic (single-gene) disorders such as cystic fibrosis and sickle cell anemia. Used by IVF physicians to inform embryo selection for couples carrying inherited genetic conditions.
• PGT-SR (Preimplantation Genetic Testing for Structural Rearrangements) A genetic test used during IVF to screen embryos for unbalanced chromosomal structures caused by inherited rearrangements such as translocations or inversions. Used by IVF physicians to identify embryos free of familial structural chromosomal abnormalities.

Quantifiable outcome

• Expanding access to advanced genetic services for families in need of PGT-SR and PGT-M testing for inherited conditions

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and supporting.

• Tandem GeneticscoreStrategic or Co-development PartnerTandem Genetics provides expert genetic counseling services seamlessly integrated with NOVA Genomics PGT testing. Through this partnership, clinics have access to experienced telehealth counselors for pre- and post-testing sessions. Genetic counselors provide clear guidance on results and next steps, ensuring patients receive comprehensive support throughout their IVF journey.
• IVF StoresupportingChannel Partner/ Reseller/ DistributorIVF Store is a full-service online IVF marketplace representing the industry's finest products and solutions. Through this partnership, NOVA Genomics PGT services are available alongside IVF Store's comprehensive offerings, giving clinics a single reliable partner for both everyday needs and next-generation genetic testing services.

Scale indicators4 records

Expansion highlights5 records

Direct peers

• Natera: Natera is one of the largest commercial providers of PGT-A, PGT-M, and PGT-SR services, operating Empower PGT and other embryo-screening products. It is the most direct head-to-head competitor to NOVA Genomics in the embryo genetic testing category, with deeper commercial scale and longer operating history.
• Igenomix (Vitrolife): Igenomix is a global PGT laboratory acquired by Vitrolife, providing PGT-A, PGT-M, and PGT-SR plus reproductive genetics services to IVF clinics worldwide. Comparable to NOVA in clinical offering, with significantly broader geographic footprint and established clinic relationships.
• Reprogenetics (CooperSurgical): Reprogenetics, part of CooperSurgical, is a long-established PGT reference lab offering PGT-A, PGT-M, and PGT-SR. One of the pioneering PGT labs and a direct competitor with strong IVF-clinic distribution through CooperSurgical's network.
• Genesis Genetics: Genesis Genetics is a specialized PGT/MDL laboratory specializing in PGT-M and PGT-SR testing with patented haplotyping methods. Closely comparable to NOVA in offering depth for monogenic and structural rearrangement cases.

Broad incumbents

• Invitae (now part of Labcorp): Invitae (acquired by Labcorp) is a broad genetic testing platform providing carrier screening and reproductive genetics tests adjacent to PGT. A broader incumbent touching the IVF/reproductive genetics ecosystem rather than direct embryo testing.
• Labcorp: Labcorp is a global diagnostics leader with reproductive and genetic testing offerings and now owns Invitae. A broad incumbent in clinical laboratory services whose size, payer relationships, and recent fertility-focused investments create competitive context for a small PGT startup.
• Sema4: Sema4 is a patient-centered health intelligence and genetic testing company offering reproductive and oncology genetic tests. Operates adjacent in reproductive genetics with broader strategic reach than NOVA.

Emerging players

• Progenity: Progenity is a molecular diagnostics company that has commercialized reproductive and prenatal genetic tests with an emerging PGT portfolio. A comparable emerging competitor with overlapping reproductive genetics focus, though narrower in PGT depth than NOVA's pure-play approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NOVA Genomics